HWHG(SH:600079) Zhi Tong Cai Jing·2025-11-03 07:49Core Viewpoint - The announcement highlights that Yichang Renfu Pharmaceutical, a subsidiary of Renfu Pharmaceutical, has received approval from the National Medical Products Administration for the clinical trial of Pregabalin sustained-release tablets, indicating a significant step in expanding its treatment applications [1] Group 1: Company Developments - Renfu Pharmaceutical's subsidiary, Yichang Renfu, holds an 80% stake and has recently received a clinical trial approval notice for Pregabalin sustained-release tablets [1] - The initial approval in 2023 was for treating diabetic peripheral neuropathy (DPN) related neuropathic pain, and the new application aims to add postherpetic neuralgia (PHN) as an indication [1] Group 2: Product Information - Pregabalin is a novel calcium channel modulator that effectively blocks voltage-dependent calcium channels, reducing neurotransmitter release [1] - The clinical applications of Pregabalin sustained-release tablets primarily target neuropathic pain associated with DPN and PHN [1]